NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Biotechnology

Healthcare
$2.80 +1.43%

+$0.06 today

Market cap
$124.12M
Beta
2.19
P/E (TTM)
-5.3
EPS (TTM)
-$0.76
52W Low $1.62High $5.06

Volume 2.09M

Average 1.27M

NRXP Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

NRx Pharmaceuticals, Inc.NASDAQ: NRXP

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $151K rose 1158.3% year over year, ahead of the +43.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 86.4% from the prior quarter. Over 3 fiscal years it compounded at -60.2% a year.

Context

  • Stock-based compensation amounted to 18.6% of revenue in FY2025.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1158.3% holds above the trailing-twelve-month pace of +43.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$151K+86.4% QoQ
Last fiscal yearDec 2025
$228K-53.1% YoY
LTMMar 2026
$367K+43.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1158.3%——
1 year-53.1%——
3-year CAGR-60.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
228K USD
Year-over-year change
-53.1%
4-year CAGR
-58.6%

Stock-Based Compensation vs competitors

How NRXP compares with its peers on the latest reported figures

  • NRXP's LTM Mar 2026 stock-based compensation of $367K is the smallest of the 9 companies compared; the peer median is $3.62M.
  • Its year-over-year change of +43.4% is the highest of 9, against a peer median of -37.2%.
  • Stock-based compensation amounts to 16.0% of revenue for NRXP, versus a peer median of 18.1%.
NRXP Competitors Peer median
Stock-Based Compensation for NRXP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$13.5M -20.7%-26.5%8.9%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$5.86M -50.8%-13.8%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$5.14M -37.3%+4.9%1543.3%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$3.79M -50.8%-5.5%18.1%
CUECue Biopharma, Inc.LTM Mar 2026$3.45M -44.6%-20.7%10.6%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$2.72M -37.2%-10.8%—
EQEquillium, Inc.LTM Mar 2026$2.63M -22.6%-21.7%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.82M +13.4%—128.8%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$367K +43.4%-60.2%16.0%
Peer median (excluding NRXP) $3.62M-37.2%-13.8%18.1%

Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(93.06M)(39.75M)(30.15M)(25.13M)(28.62M)
Depreciation & Amortization2K4K5K5K143K
Deferred Income Tax00000
Stock-Based Compensation7.79M3.63M387K486K228K
Change in Working Capital(4.9M)699K5.16M5.29M1.41M
Accounts Receivables831K00048K
Inventory00000
Accounts Payables(19K)(1.61M)2.66M(5.22M)113K
Other Working Capital(5.71M)2.31M2.51M10.51M1.25M
Other Non-Cash Items52.47M(4.33M)2.94M8.71M12.73M
Operating Cash Flow(37.7M)(39.76M)(21.66M)(10.64M)(14.11M)
Capital Expenditures(7K)(10K)(3K)00
Acquisitions (Net)0000(2.38M)
Purchases of Investments0000(432K)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(7K)(10K)(3K)0(2.81M)
Debt Repayment(1.28M)9.5M(3.09M)(1.5M)7.42M
Common Stock Issued36.98M22.7M8.12M5.91M15.86M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities27.75M10K03.07M0
Financing Cash Flow63.46M32.21M6.2M7.49M23.28M
Effect of Forex Changes00000
Net Change in Cash25.75M(7.55M)(15.46M)(3.15M)6.35M
Free Cash Flow(37.71M)(39.77M)(21.66M)(10.64M)(14.11M)

NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.